NCT06425159
Terminated
Phase 2
A Phase 2/3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of BHV-7000 as Adjunctive Therapy in Subjects With Idiopathic Generalized Epilepsy With Generalized Tonic-clonic Seizures, With Open-label Extension
Biohaven Therapeutics Ltd.221 sites in 2 countries27 target enrollmentStarted: June 20, 2024Last updated:
ConditionsGeneralized Epilepsy
Overview
- Phase
- Phase 2
- Status
- Terminated
- Sponsor
- Biohaven Therapeutics Ltd.
- Enrollment
- 27
- Locations
- 221
- Primary Endpoint
- Time to the Second Day with a Generalized Tonic Clonic (GTC) Seizure During the 24- week Double-blind Treatment Period
Overview
Brief Summary
The purpose of this study is to determine whether BHV-7000 is effective in the treatment of idiopathic generalized epilepsy with generalized tonic-clonic seizures and includes an additional open-label extension (OLE) phase.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Eligibility Criteria
- Ages
- 18 Years to 75 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Male and Female participants 18 to 75 years of age at time of consent.
- •Diagnosis of Idiopathic Generalized Epilepsy at least 6 months prior to the screening visit, defined by 2017 International League Against Epilepsy (ILAE) Classification and based on requirements of Epilepsy Adjudication criteria.
- •Subject has probable GTC seizures in the setting of IGE, meaning GTC seizures and either classic 3-4 Hz generalized spike-wave (GSW) or 4-6 Hz polyspike-wave on EEG and no focal abnormality (asymmetric spike-wave fragment is allowed) AND/OR a clear history of absence seizures or myoclonic jerks
- •Subjects with possible GTC seizures in the setting of IGE, meaning GTC and either Normal EEG OR Generalized epileptiform EEG abnormality with atypical spike-wave and no focal abnormality (asymmetric spike-wave fragment is allowed).
- •Subject meets the 2009 ILAE definition of drug resistant epilepsy, failure of adequate trials of two tolerated and appropriately chosen and used ASM schedules (whether as monotherapies or in combination) to achieve sustained seizure freedom.
- •Ability of subject or caregiver to keep accurate seizure diaries
- •Current treatment with at least 1 to 3 ASMs as part of no more than 4 epilepsy treatments in total (e.g., each ASM is considered 1 treatment. Other epilepsy therapies including devices and diet therapy are allowed; together these other therapies count as 1 treatment).
- •Accurate history of having at least 3 days with a GTC seizure evenly spread throughout the 16 weeks prior to the screening visit, such that a subject had at least 1 day with a GTC seizure during the first 8 weeks and at least 1 day with a GTC seizure during the second 8 weeks.
Exclusion Criteria
- •History of status epilepticus (convulsive status epilepticus for \> 5 minutes or focal status epilepticus with impaired conscious for \> 10 minutes) within the last 6 months prior to screening visit that is not consistent with the subject's habitual seizure.
- •History of repetitive/cluster GTC seizures (where individual seizures cannot be counted) within the last 6 months prior to screening visit, or having repetitive/cluster GTC seizures count during the screening phase.
- •Any condition that would interfere with and/or confound the interpretation of safety or efficacy data from the study, as judged by the Investigator
Arms & Interventions
BHV-7000 75 mg
Active Comparator
Intervention: BHV-7000 (Drug)
Placebo
Placebo Comparator
Intervention: Placebo (Drug)
Outcomes
Primary Outcomes
Time to the Second Day with a Generalized Tonic Clonic (GTC) Seizure During the 24- week Double-blind Treatment Period
Time Frame: Baseline to Week 24 of Double-Blind Treatment Period
To compare the efficacy of BHV-7000 to placebo as adjunctive therapy for subjects with idiopathic generalized epilepsy with generalized tonic-clonic (GTC) seizures as measured by the time to the second day with a GTC seizure during the double-blind phase
Secondary Outcomes
- Percentage of Participants with freedom of GTC seizures during DBT Phase(Baseline to Week 24 of Double-Blind Treatment Period)
- Number of Participants With Clinically Significant Laboratory Abnormalities(Baseline to Week 24 of Double-Blind Treatment Period)
- Number of Participants With Deaths, Serious AEs (SAEs), AEs Leading to Study Drug Discontinuation, and moderate or severe AEs(Baseline to Week 24 of Double-Blind Treatment Period)
Investigators
Study Sites (221)
Loading locations...
Similar Trials
Completed
Phase 2
Efficacy and Safety Study of BHV-7000 Monotherapy in Major DepressionMajor Depressive DisorderNCT06419608Biohaven Therapeutics Ltd.336
Completed
Phase 2
BHV-7000 Acute Treatment of Bipolar ManiaBipolar DisorderNCT06419582Biohaven Therapeutics Ltd.274
Recruiting
Phase 2
A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset EpilepsyNCT06132893Biohaven Therapeutics Ltd.390
Recruiting
Phase 2
Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset EpilepsyNCT06309966Biohaven Therapeutics Ltd.390
Completed
Phase 3
Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2Hepatitis C, ChronicNCT01728324Boehringer Ingelheim496